Cantitate/Preț
Produs
Total produse
Vezi coșul
Epigenetic Therapy of Cancer: Preclinical Models and Treatment Approaches de Michael Lübbert

Epigenetic Therapy of Cancer: Preclinical Models and Treatment Approaches

Editat de Michael Lübbert, Peter A. Jones
en Limba Engleză Paperback – 24 sep 2016
The growing knowledge about disturbances of epigenetic gene regulation in hematopoietic stem cell disorders is now being translated into treatment approaches that target the epigenetic defects pharmacologically. This book first presents the latest evidence regarding the epigenetic regulation of hematopoietic stem cell differentiation and hemoglobin production. The significance of DNA methylation abnormalities in hematopoietic disorders and of epigenetic disturbances in lung cancer and other solid tumors is then discussed. A major part of the book, however, relates specifically to the translation of basic research and drug development to clinical applications, and in this context both present and future clinical strategies are considered. Individual chapters are devoted to the use of DNA hypomethylating agents and chromatin-modifying agents, and the treatment of hematologic malignancies and solid tumors by means of epigenetic agents is discussed in detail.
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 103337 lei  6-8 săpt.
  Springer Berlin, Heidelberg – 24 sep 2016 103337 lei  6-8 săpt.
Hardback (1) 73092 lei  6-8 săpt.
  Springer Berlin, Heidelberg – 15 ian 2014 73092 lei  6-8 săpt.

Preț: 103337 lei

Preț vechi: 108776 lei
-5% Nou

Puncte Express: 1550
Preț estimativ în valută:
19778€ • 20568$ • 16550£

Carte tipărită la comandă

Livrare economică 14-28 martie

 Adaugă în coș

Wish list
Gift list
Am citit!
Adaugă în listă
Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783662519288
ISBN-10: 3662519283
Pagini: 335
Ilustrații: X, 325 p. 48 illus., 14 illus. in color.
Dimensiuni: 155 x 235 x 18 mm
Greutate: 0.47 kg
Ediția:Softcover reprint of the original 1st ed. 2014
Editura: Springer Berlin, Heidelberg
Colecția Springer
Locul publicării:Berlin, Heidelberg, Germany

Cuprins

The fundamental role of epigenetic regulation for normal and disturbed all growth and differentiation.- Mouse models to study DNA methylation in cancer research.- Epigenetic regulation of normal hematopoietic development.- Epigenetic regulation of globin genes and disturbances in hemoglobinopathies.- DNA methylation abnormalities in hematopoietic disorders: biological significance and methodological approaches.- Epigenetic modifications mediated by the AML1/ETO and MLL leukemia fusion proteins.- Epigenetic abnormalities in lung cancer.- Pharmacodynamic Responses to DNA Methyltransferase Inhibition.- Histone Methyltransferases: Opportunities in Cancer Drug Discovery.- Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.- Clinical Implications of Epigenetic Alterations in Lung Cancer.- Epigenetic disturbances in colorectal cancer.- Epigenetic Therapies in Solid Tumours: from preclinical models to clinical trial results.

Recenzii

From the reviews:
“This new book covers the timely topic of epigenetic therapy. … The combination of articles describing the basic science framework of epigenetics and the detailed summaries of clinical trials with epigenetic drugs is attractive for a wide readership, ranging from medical students to scientists who are interested in translational studies to clinicians who work for the direct benefit of cancer patients. … This high-quality book is an excellent overview of the current success and future promise of epigenetic therapy.” (Gerd Pfeifer, Doody’s Book Reviews, May, 2014)

Textul de pe ultima copertă

The growing knowledge about disturbances of epigenetic gene regulation in hematopoietic stem cell disorders such as myeloid leukemias and preleukemias (myelodysplasias) is now being translated into treatment approaches that target the epigenetic defects pharmacologically. Such approaches include reactivation of tumor suppressor genes and other antiproliferative genes by reversal of DNA hypermethylation through azanucleosides, and use of HDAC inhibitors to reverse gene silencing mediated by chimeric, leukemia-specific transcription factors.
This book first presents the latest evidence derived from preclinical models regarding the epigenetic regulation of hematopoietic stem cell differentiation and hemoglobin production. The significance of DNA methylation abnormalities in hematopoietic disorders and of epigenetic disturbances in lung cancer and other solid tumors is then discussed. A major part of the book, however, relates specifically to the translation of basic research and drug development to clinical applications, and in this context both present and future clinical strategies are considered. Individual chapters are devoted to the use of DNA hypomethylating agents and chromatin-modifying agents, and the treatment of hematologic malignancies and solid tumors by means of epigenetic agents is discussed in detail.

Caracteristici

Devotes detailed attention to the translation of basic research and drug development to clinical applications in the treatment of solid tumors as well as hematologic malignancies and hemoglobinopathy Presents the latest evidence derived from preclinical models regarding the epigenetic regulation of hematopoietic stem cell differentiation and hemoglobin production Discusses DNA methylation abnormalities in depth